SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, Newswire, David Smith, Tim Crawford

News Feed Item

Dangerous Drugs Lawyer Ken Rothweiler Lauds Warning Label Recommendation for Testosterone-Boosting Drugs

PHILADELPHIA, March 12, 2014 /PRNewswire/ -- According to an Associated Press article on February 24, 2014, the consumer advocacy group Public Citizen is calling on the FDA to add a bold, black warning label to popular testosterone-boosting drugs.

This call comes on the heels of a study published in January in the journal PLOS One finding that testosterone replacement therapies double the risk of heart attacks in men over age 65 and triple the risk of heart attacks for younger men with pre-existing heart conditions.

"Testosterone drugs are supposed to help the men who are prescribed them, and instead research has shown they may cause heart injuries, heart attacks and strokes," said dangerous drugs lawyer Ken Rothweiler.

According to the FDA, prescription testosterone is only advised for men with demonstrated low testosterone levels and an associated medical condition known as "hypogonadism." But largely due to drug manufacturers' advertising, the number of testosterone prescriptions given to American men has tripled since 2001. According to The New York Times, sales were estimated at $2 billion in 2012. That same year, three million prescriptions were written for the market leader AndroGel® alone.

"Because of the lack of a warning, doctors aren't always aware of the risks when they prescribe these medications to patients," Rothweiler said.  "I support the Public Citizen's call and applaud their push to warn consumers and physicians about the possible side effects of low testosterone therapies."

Ken Rothweiler is part of a legal team comprised of him, Alex MacDonald and Jon Ostroff all leaders of law firms with many years of experience handling drug injury cases against big pharmaceutical companies. Together, the Rothweiler, MacDonald, and Ostroff led team is providing quality legal representation for the victims of testosterone-boosting products. For more information, visit

SOURCE Ken Rothweiler

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.